Wednesday, March 05, 2008

Review Determines Measles, Mumps and Rubella Vaccine Lots Can be Released for Use

From Health Canada:
Health Canada has recently completed its review of Merck Frosst’s reports pertaining to a lot (1529U) of measles, mumps and rubella (MMR) vaccine potentially associated with six cases of suspected anaphylaxis in young adults in Alberta during November and December 2007. The review found no link between this vaccine lot and the adverse events in Alberta.

Based on this information, the suspension of this lot (1529U) and two other associated lots (1528U and 1680U) have been lifted and are available for use by provinces and territories to vaccinate both adults and children requiring MMR immunization. Health Canada had asked provincial and territorial health authorities and all other Canadian vaccine providers on December 11, 2007 not to use these lots of the MMR-II vaccine sold by Merck Frosst Canada. At that time, Health Canada requested that Merck Frosst Canada provide a written report on any manufacturing or safety problems associated with Lot 1529U and its bulk components to complement other ongoing investigative efforts. ...more

No comments: